Bristol-Myers Squibb was founded in 1887 and is headquartered in New York, US

Chief Executive Officer

Executive Vice President, CFO

Executive Vice President and Chief Scientific Officer

Chairman, Board of Directors

Bristol-Myers Squibb has offices in New York, Jacksonville, Atlanta, Birmingham and in 176 other locations

New York, US (HQ)

345 Park Avenue

Bristol-Myers Squibb's revenue was reported to be $19.4 b in FY, 2016

USD

## Revenue (Q3, 2017) | 5.3 b |

## Gross profit (Q3, 2017) | 3.7 b |

## Gross profit margin (Q3, 2017), % | 70% |

## Net income (Q3, 2017) | 856 m |

## Market capitalization (11-Dec-2017) | 103.3 b |

## Cash (30-Sep-2017) | 4.6 b |

## EV | 105.6 b |

Bristol-Myers Squibb's current market capitalization is $103.3 b.

USD | FY, 2013 | FY, 2014 | FY, 2015 | FY, 2016 |
---|---|---|---|---|

## Revenue | 16.4 b | 15.9 b | 16.6 b | 19.4 b |

## Revenue growth, % | (3%) | 4% | 17% | |

## Cost of goods sold | 4.6 b | 3.9 b | 3.9 b | 4.9 b |

## Gross profit | 11.8 b | 11.9 b | 12.7 b | 14.5 b |

USD | Q3, 2013 | Q1, 2014 | Q2, 2014 | Q3, 2014 | Q1, 2015 | Q2, 2015 | Q3, 2015 | Q1, 2016 | Q2, 2016 | Q3, 2016 | Q1, 2017 | Q2, 2017 | Q3, 2017 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|

## Revenue | 4.1 b | 3.8 b | 3.9 b | 3.9 b | 4 b | 4.2 b | 4.1 b | 4.4 b | 4.9 b | 4.9 b | 4.9 b | 5.1 b | 5.3 b |

## Cost of goods sold | 1.2 b | 968 m | 991 m | 1 b | 847 m | 1 b | 1.1 b | 1.1 b | 1.2 b | 1.3 b | 1.3 b | 1.6 b | 1.6 b |

## Gross profit | 2.9 b | 2.8 b | 2.9 b | 2.9 b | 3.2 b | 3.2 b | 3 b | 3.3 b | 3.7 b | 3.6 b | 3.7 b | 3.6 b | 3.7 b |

## Gross profit Margin, % | 71% | 75% | 75% | 74% | 79% | 76% | 73% | 76% | 75% | 73% | 74% | 70% | 70% |

USD | FY, 2013 | FY, 2014 | FY, 2015 | FY, 2016 |
---|---|---|---|---|

## Cash | 3.6 b | 5.6 b | 2.4 b | 4.2 b |

## Inventories | 1.5 b | 1.6 b | 1.2 b | 1.2 b |

## Current Assets | 18.9 b | 14.6 b | 10.4 b | 13.7 b |

## Goodwill | 7.1 b | 7 b | 6.9 b | 6.9 b |

USD | Q2, 2015 | Q3, 2015 | Q1, 2016 | Q2, 2016 | Q3, 2016 | Q1, 2017 | Q2, 2017 | Q3, 2017 |
---|---|---|---|---|---|---|---|---|

## Cash | 4.2 b | 4 b | 2.6 b | 2.9 b | 3.4 b | 3.9 b | 3.5 b | 4.6 b |

## Inventories | 1.3 b | 1.1 b | 1.3 b | 1.4 b | 1.5 b | 1.4 b | 1.2 b | 1.3 b |

## Current Assets | 13.1 b | 12.9 b | 11.2 b | 12.3 b | 13.2 b | 13.6 b | 14.3 b | 15 b |

## Goodwill | 7 b | 7 b | 6.9 b | 6.9 b | 6.9 b | 6.9 b | 6.9 b | 6.9 b |

USD | FY, 2013 | FY, 2014 | FY, 2015 | FY, 2016 |
---|---|---|---|---|

## Net Income | 2.6 b | 2 b | 1.6 b | 4.5 b |

## Inventories | (45 m) | (254 m) | 97 m | (152 m) |

## Accounts Payable | 412 m | (44 m) | (919 m) | 104 m |

## Cash From Operating Activities | 3.5 b | 3.1 b | 1.8 b | 2.9 b |

USD | Q3, 2013 | Q1, 2014 | Q2, 2014 | Q3, 2014 | Q1, 2015 | Q2, 2015 | Q3, 2015 | Q1, 2016 | Q2, 2016 | Q3, 2016 | Q1, 2017 | Q2, 2017 | Q3, 2017 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|

## Net Income | 1.8 b | 936 m | 1.3 b | 2 b | 1.2 b | 1.1 b | 1.8 b | 1.2 b | 2.4 b | 3.6 b | 1.5 b | 2.4 b | 3.3 b |

## Inventories | (8 m) | (144 m) | (157 m) | (162 m) | 51 m | 162 m | 231 m | (44 m) | (111 m) | (107 m) | (71 m) | (58 m) | 7 m |

## Accounts Payable | 301 m | (12 m) | (112 m) | 63 m | (83 m) | (618 m) | (1.2 b) | (77 m) | (36 m) | (142 m) | (114 m) | (85 m) | 63 m |

## Cash From Operating Activities | 2.1 b | 1.7 b | 2.6 b | 626 m | 697 m | 1.2 b | 25 m | 1.4 b | 2.4 b | 4.2 b |

USD | Y, 2017 |
---|---|

## EV/CFO | 25.4 x |

## EV/FCF | 31.5 x |

## Revenue/Employee | 210.2 k |

## Financial Leverage | 2.3 x |

Y, 2015 | Y, 2016 | |
---|---|---|

## Phase III Trials | 2 | 8 |

## Projects in R&D Pipeline | 32 | 44 |

Source: 359 public H-1B filings from Bristol-Myers Squibb

Search term - Bristol-Myers Squibb